In Case You Missed It: Gold, uranium and a sudden leadership spill are driving the news today
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar.
Below is a wrap of the top 20-ish performing stocks, by percentage, that made announcements today.
Koonenberry Gold (ASX:KNB) revealed that final approvals have been received for the maiden drilling program at its Atlantis Au-Cu Prospect, and “as soon as weather conditions permit” they’ll get the machinery spun up to conduct first pass Air Core drilling at the site.
BMG Resources (ASX:BMG) has dropped news that long-time MD Bruce McCracken has resigned from BMG and all of its subsidiaries, with major shareholder John Prineas assuming the role of non-executive chairman and day-to-day overseer until a new CEO or MD is brought on board.
Aerometrex (ASX:AMX) delivered a quarterly this morning, saying it expects to deliver a record first half (1H) revenue outcome, driven by “strong ongoing performance of the LiDAR and MetroMap product lines”, somewhere around the $11.8-$12.2 million range, a tidy climb from the previous years’ $10 million high water mark.
White Cliff Minerals (ASX:WCN) is up today, after delivering an investor presentation covering yesterday’s big news about plans to acquire a historical uranium project in the Northwest Territories of Canada called Radium Point.
GTI Energy (ASX:GTR) has informed the market that it has appointed experienced Denver-based ISR uranium technical and executive leader Matt Hartmann as President of US Operations, as the company prepares a very timely resources upgrade at the Lo Herma ISR uranium project in Wyoming.
Venture Minerals (ASX:VMS) has wrapped up Stage 1 resource drilling at its large-scale Jupiter clay-hosted rare earths prospect in WA’s Mid-West region, with that action propelling the company towards the 70% mark of a JV option that would end up with 90% of the project in Venture’s hands by the end of the deal.
Toro Energy (ASX:TOE) took time this morning to let the market know that things have been happening, and that its Extension Study to the proposed Lake Maitland Uranium-Vanadium operation, located approximately 105km southeast of the Wiluna township in Western Australia, has “significantly advanced”.
Lumos Diagnostics (ASX:LDX) climbed today, as we enter Day 5 of the company’s ever-lengthening explanation of what last week’s news of a deal with Hologic actually means for the company. For those of you playing at home, I’m as confused as you are.
And DroneShield (ASX:DRO) is – unsurprisingly, given the current geopolitical climate – flying high, delivering a solid quarterly showing that it’s banked record revenues of $55.1m for 2023 thus far, up 3x compared to the whole of 2022, with 80% of revenues coming from repeat customers, mostly from the United States (68%) and Australia (23%).
More Top Small Cap Stories: Monday
Taiton Resources (ASX:T88) has applied for exploration licences over the advanced high-grade Kingsgate project in NSW, taking in exploration licences ELA6699 and ELA6702 that have a total area of 309.8km2, as the company ramps up its hunt for increasingly precious molybdenum, and as the market size climbs from an estimated US$315bn in 2023.
Olympio Metals (ASX:OLY) released its first set of assays from from a first phase of aircore drilling at the Walloway prospect in South Australia, and has confirmed REE and niobium mineralisation with total rare earth oxide grades (TREO) up to 5,011ppm.
Melodiol Global Health (ASX:ME1) has revealed a quarterly report today, showing $2.13m in unaudited revenue generated in Q4 FY2023, which marks a 15% rise on Q3 and a 101% increase on Q4 FY2022, and which Melodial attributes to highest ever achieved sales by the division off the back of the group’s increased brand recognition and established market footprint.
Meanwhile, Alicanto Minerals’ (ASX:AQI) Swedish monster just won’t stop getting bigger, with the company announcing that its Skyttgruvan-Naverberg project is looking increasingly like it is part of the same system as the historical Falun deposit which once produced 28Mt at 4% copper, 4g/t gold, 5% zinc, 2% lead and 35g/t silver since it started producing 1,000 (no, really) years ago.
And clinical-stage biotech PharmAust (ASX:PAA) is now partnering with leading MND/ALS clinical study design and statistical analysis specialists Berry Consultants – a company that brings with it a strong track record of innovative clinical trial design and experience with the FDA – as PAA focuses on moving forward its Phase 2/3 MND/ALS study in 2024.
At Stockhead we tell it like it is. While Alicanto, Melodiol Global Health, GTI Energy, PharmAust, Olympio and Taiton are Stockhead advertisers, they did not sponsor this article – and, for what it’s worth, I’m flat out remembering what I had for breakfast this morning – so I’m pretty much flying in the dark, anyway.